Emily N Kinsey1, Tian Zhang2, Andrew J Armstrong2. 1. From the Department of Medicine, Duke University. 2. Divisions of Medical Oncology and Urology, Duke Cancer Institute, Durham, NC.
Abstract
PURPOSE: In recent years, the treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) have expanded significantly. In addition to androgen deprivation therapy, the systemic treatments now include docetaxel, abiraterone, enzalutamide, and apalutamide. Radiation to the primary is also an option for select low-volume patients. METHODS: We conducted a review of the pivotal trials that have changed the practice of mHSPC. RESULTS: We describe an overview of the trials that investigated docetaxel (CHAARTED and STAMPEDE-Docetaxel), abiraterone (LATTITUDE and STAMPEDE-Abiraterone), enzalutamide (ARCHES, ENZAMET), apalutamide (TITAN), and radiation to the primary (STAMPEDE-Radiation). DISCUSSION: The treatment of mHSPC is a complex topic, and treatment choice should be individualized. Patient preferences, cost, volume of disease, and side effect profiles are important in determining which option is the best for an individual patient.
PURPOSE: In recent years, the treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) have expanded significantly. In addition to androgen deprivation therapy, the systemic treatments now include docetaxel, abiraterone, enzalutamide, and apalutamide. Radiation to the primary is also an option for select low-volume patients. METHODS: We conducted a review of the pivotal trials that have changed the practice of mHSPC. RESULTS: We describe an overview of the trials that investigated docetaxel (CHAARTED and STAMPEDE-Docetaxel), abiraterone (LATTITUDE and STAMPEDE-Abiraterone), enzalutamide (ARCHES, ENZAMET), apalutamide (TITAN), and radiation to the primary (STAMPEDE-Radiation). DISCUSSION: The treatment of mHSPC is a complex topic, and treatment choice should be individualized. Patient preferences, cost, volume of disease, and side effect profiles are important in determining which option is the best for an individual patient.
Authors: Christian Thomas; Martin Baunacke; Holger H H Erb; Susanne Füssel; Kati Erdmann; Juliane Putz; Angelika Borkowetz Journal: Cancers (Basel) Date: 2021-12-21 Impact factor: 6.639
Authors: Keiichiro Mori; Hadi Mostafaei; Reza Sari Motlagh; Benjamin Pradere; Fahad Quhal; Ekaterina Laukhtina; Victor M Schuettfort; Gero Kramer; Mohammad Abufaraj; Pierre I Karakiewicz; Takahiro Kimura; Shin Egawa; Shahrokh F Shariat Journal: BJU Int Date: 2021-07-21 Impact factor: 5.969